![Cancer Therapy Advisor – Results, from the STARGLO trial presented at EHA2024 by Dr Jeremy Abramson](https://oncodaily.com/pub/uploads/2024/06/Screenshot_19-6-2024_191937_researchers.mgh_.harvard.edu_-e1718810612288.png)
Photo taken from researchers.mgh.harvard.edu
Jun 21, 2024, 07:58
Cancer Therapy Advisor – Results, from the STARGLO trial presented at EHA2024 by Dr Jeremy Abramson
Cancer Therapy Advisor shared a post on X:
“Glofitamab plus GemOx improved outcomes over rituximab plus GemOx in transplant-ineligible patients with relapsed/refractory DLBCL. These results, from the STARGLO trial, were presented at EHA2024 by Dr Jeremy Abramson from Mass General Cancer Center.”